

VU Research Portal

Biological risk factors and sleep-related risk factors of type 2 diabetes mellitus

Jansen-Koopman, A.D.M.

2019

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Jansen-Koopman, A. D. M. (2019). *Biological risk factors and sleep-related risk factors of type 2 diabetes mellitus: To refine characterization of high risk subjects and to identify novel risk factors.*

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Chapter 1

General introduction



Diabetes Mellitus

Diabetes Mellitus is a chronic, metabolic disease characterized by elevated levels of blood glucose, which over time leads to serious damage of the heart, blood vessels, eyes, kidneys and nerves. The number of people with diabetes nearly quadrupled since 1980 to 425 million people in 2017 and it is estimated to increase to an impressive number of 629 million people in 2045 [1]. Type 2 Diabetes Mellitus (T2DM) accounts for more than 90% of the people with diabetes [2]. T2DM results from the body's ineffective use of insulin and is characterized by deficient beta-cell function, insulin resistance, impaired insulin secretion and hyperglycemia [2].

However, several heterogeneous processes underlie the pathophysiology of T2DM [3]. This is evident from the fact that among people with prediabetes, defined as those not meeting the threshold for diabetes, only about 5-15% annually will actually progress to T2DM [4], while the remainder converts back to normoglycemia or remains at levels associated with prediabetes. According to an ADA expert panel, approximately 70% of people with prediabetes will develop T2DM eventually [5]. This suggests that there are different underlying pathophysiological processes underlying T2DM. Indeed, some of these processes are predominantly associated with obesity and insulin resistance, while others are associated with a loss of beta cell function as the primary abnormality [6]. Hence, information on the different mechanisms that play a role in the development of T2DM is essential for personalized T2DM prevention strategies and T2DM precision medicine and underlines the need to refine the characterization of people who will develop T2DM. For example, Ahlqvist et al. 2018 [7] identified five clusters (severe autoimmune diabetes, severe insulin-deficient diabetes, severe insulin-resistant diabetes, mild obesity-related diabetes and mild-age related diabetes), characterized by different abnormalities, of people with T2DM with differing disease progression and risk of diabetes complications, which could help to tailor and target early treatment. In this thesis, we will examine non-modifiable biological factors that may contribute to elucidating the heterogeneity in the pathophysiological processes to incident T2DM.

Risk factors for T2DM

T2DM results from a complex interaction between genetic, environmental and lifestyle factors. Numerous factors have been associated with the development of T2DM and among them several are considered established risk factors for T2DM.

First, it is well accepted that T2DM has an important *genetic component*. The high concordance rates of T2DM observed in identical twins support the involvement of genetic factors in the development of T2DM [8, 9]. Although a specific gene or genes have yet to be found, genome-wide association studies (GWAS) have successfully identified susceptibility loci associated with T2DM and related metabolic characteristics, which together explain about 10% of the heritable component of T2DM risk [9, 10].

A second well-known risk factor is *ethnicity*. Among ethnic minority groups, such as African, Turkish, Moroccan, and particularly South-Asian origin groups, a higher prevalence of T2DM is observed as compared with European host populations [11-13]. The prevalence of T2DM also differs between ethnic groups in the Netherlands. For example, men of different ethnic minority groups had 3 to 8 times higher odds to have T2DM and for women the odds were 6 to 12 times higher, compared to Caucasian participants [12].

A third risk factor is *age*. For years, T2DM was known as “older-onset diabetes,” emphasizing that the prevalence of T2DM increases with age. Impaired beta-cell compensation in the context of age-related insulin resistance predisposes older people to develop T2DM [14]. However, in the last years, the age of T2DM diagnosis is decreasing [15]. This is mainly due to our current lifestyle patterns that result in obesity and less physical activity.

The fourth and leading risk factor for T2DM is *obesity* [16]. The risk of T2DM is not only determined by the degree of obesity, but also by the location of the fat accumulation. A recent Japanese population-based study [17] revealed that compared to non-obese group, obesity and visceral fat obesity alone each had little effect on the risk of incident T2DM with a Hazard Ratio (HR) of around 1.8 and 2.3, but that the presence of ectopic fat obesity resulted in the greatest risk of incident T2DM, with a HR of 4.7 (95%CI: 1.9–11.7) in men and 14.0 (7.2–27.1) in women. The pathophysiology linking obesity and diabetes is in generally attributed to insulin resistance and insulin deficiency [18]. In addition, free fatty acids (FFAs) play an important role. An *unhealthy lifestyle* is a fifth risk factor for T2DM.

Lifestyle factors

Lifestyle factors, such as smoking, physical inactivity, sedentary lifestyle and dietary intake are among the most important modifiable factors that have been suggested to play a role in the development of obesity and in turn T2DM. *Smoking* increases the risk of T2DM by around 30% for active smokers, compared to nonsmokers [19]. *Physical inactivity* refers to insufficient levels of moderate to vigorous intensity physical activity, so not meeting the recommendation of physical activity of at least 150 minutes moderate intensity or 75 minutes vigorous intensity physical activity per week [20], while *sedentary behavior* refers to prolonged sitting [21]. A recent meta-analysis reported a dose-response relation of physical activity with a pooled risk reduction of 26% (95%CI: 20-31%) for T2DM among those who adhered to the physical activity recommendations, compared to inactive people [22]. In addition, a significant association between sedentary time and incidence of T2DM with a pooled HR of 1.9 (95%CI: 1.6-2.2) was shown [23]. The underlying mechanism suggests that physical inactivity induces weight gain, obesity and eventually T2DM. Furthermore, sedentary behavior, in particular television viewing, is

also associated with unhealthy eating [24], aggravating the predisposition to obesity and T2DM.

In addition to being associated with sedentary behavior, *an unhealthy diet* is thought to be an important independent risk factor for the development of T2DM. When single food items are investigated, consumption of red meat [25], processed meat [26] and sugar sweetened beverages [27-29] are associated with an increased risk of T2DM, whereas consumption of fruits [30], vegetables [31] and whole grains [32, 33] are associated with a reduced T2DM risk [34]. When studying dietary patterns, the western diet, which is characterized by high consumption of red and processed meat, high fat dairy products, French fries, sweets and desserts, was associated with an increased T2DM risk independent of BMI, physical activity, age and family history (Relative Risk(RR): 1.6; 95%CI: 1.3-1.9)[35]. In contrast, a prudent diet, characterized by higher consumption of vegetables, fruit, fish, poultry and whole grains, resulted in a reduced risk (RR: 0.8; 95%CI: 0.7-1.0)[35].

A novel lifestyle factor that is suggested to be associated with risk of T2DM is sleep, which we will further investigate in this thesis.

Characterizing different pathophysiological processes of T2DM

Besides insulin, a variety of other biological factors are involved in the maintenance of glucose metabolism. To date, these factors however received less attention in relation with the development of T2DM than insulin. Among these biological factors are the incretin hormones, glucagon and GAD65 antibodies. A better understanding of the underlying processes associated with the development of T2DM, and in particular the possible role of glucagon, incretin hormones and GAD65 antibodies, could further refine the characterization of people who are at high risk of T2DM. In addition, people with T2DM also show differences in treatment responses and not all people achieve good glycemic control with their current treatment. Therefore, knowledge on glucagon, incretin hormones and GAD65 antibodies could also contribute to developing targeted prevention strategies and to a better guiding of treatment choices.

The two most important **incretin hormones** are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Food intake stimulates the secretion of these incretin hormones, which in turn regulate the release of both insulin and glucagon from pancreatic islet cells in order to control blood glucose levels. The important role of the incretin hormones with regard to insulin secretion becomes apparent when the same amount of glucose is infused intravenously as opposed to orally ingested; oral glucose enhances insulin secretion much more than infused glucose: the so-called incretin effect [36, 37]. However, in people with T2DM, the incretin effect is severely reduced [38]. Given the gluoregulatory actions of the incretin hormones and their importance in maintaining glucose homeostasis, it was hypothesized that impaired

incretin responses could be associated with the future development of T2DM, however this is yet to be studied.

Contrary to the beta-cells that release insulin, the pancreatic alpha-cells release **glucagon**, which breaks down hepatic glycogen and thereby releasing glucose to maintain glucose levels when blood glucose levels drop. Dysregulated release of glucagon by alpha-cells, which shows as increased fasting glucagon levels and reduced suppression of glucagon after a meal, contributes to the development of hyperglycaemia [39]. Because these abnormal glucagon responses already exist in people with prediabetes [40-42], impaired glucagon suppression could be associated with increased future risk of T2DM, however this is yet to be studied.

GAD65 antibodies, which are involved in the regulation of the beta-cells of the pancreas, are autoantibodies against the enzyme glutamic acid decarboxylase (GAD) [43]. GAD is involved in the production of the neurotransmitter gamma-aminobutyric acid (GABA). It is known that in T2DM, autoimmunity for GAD65, reflected by GAD65 antibody positivity, is associated with rapid progression to insulin deficiency [44-47]. In people without diabetes, GAD65 antibody positivity was associated with a decrease in maximal insulin secretory capacity, suggesting that the presence of GAD65 antibodies is a pancreatic marker of a subclinical autoimmune process which could lead to insulin deficiency and T2DM [48]. Several prospective studies [49-53] investigated the association of GAD65 antibody positivity with incident T2DM with inconsistent results. In this thesis, we will further explore whether GAD65 antibody positivity is associated with future risk of T2DM.

Novel risk factors for T2DM

While physical inactivity and diet are established lifestyle related risk factors for T2DM, sleep is a relatively novel lifestyle factor that is suggested to be associated with T2DM. In today's society the prevalence of impaired sleep has been increasing [54, 55]. A recent meta-analysis conducted in the Netherlands, revealed that in 2017, 7-28% of the general adult population reported to have a specific form of impaired sleep, namely insomnia symptoms [56]. Insomnia is defined as chronic difficulty of falling asleep, staying asleep or waking up early, despite opportunity to sleep, for at least 3 times a week during 1 month, resulting in daytime impairment [57]. Several forms of impaired sleep, it being short sleep, long sleep, insomnia, napping, circadian rhythm disturbances, affect a wide range of body functions, including metabolic health and the endocrine system [58-63].

Impaired sleep as risk factor for T2DM is thought to be mediated by several mechanisms. First, impaired sleep is thought to affect the secretion of the hormones ghrelin and leptin [64]. As both hormones play an important role in regulating hunger and appetite, elevated hunger and appetite could lead to obesity and in turn increases insulin resistance, thereby predisposing people to T2DM [62]. Second, impaired sleep is

associated with daytime fatigue and sleepiness, thereby reducing physical activity and increasing weight gain [65]. Third, impaired sleep is thought to affect the stress response system. Hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis or sympathetic activation leads to an increase in cortisol levels, which in turn contributes to insulin resistance, dyslipidemia and obesity [65]. Fourth, impaired sleep might cause decreased brain glucose utilization, which leads to hyperglycemia [66].

To date, when examining impaired sleep, sleep duration is most often investigated, making it the most established impaired sleep risk factor for developing T2DM. Insomnia is the second most important factor, which is predominantly studied in people without T2DM. A recent meta-analysis showed a clear pattern for impaired sleep as a risk factor for developing T2DM; ranging from an increased risk of 28% in people with sleep duration of ≤ 5 -6h, compared to 6-8h per night to 84% in those with insomnia compared to those without [67]. The studies that analyzed the prevalence of insomnia in people with T2DM showed inconsistent results, ranging from 6 [68] to 80% [69] and its association with metabolic parameters and glycemic control in people with T2DM are largely unknown, and therefore will be studied in this thesis.

Additionally, there are several less known forms of impaired sleep for which there is not so much evidence on the association with T2DM. Among them is **social jetlag**, which is a less-known and less extreme form of disturbed circadian rhythm, compared to shift work and travelling to time zones. Social jetlag represents the discrepancy between circadian and social clocks, in the way that people often use alarm clocks and/or medication to align their sleep and wake times with social obligations rather than with their internally regulated sleep wake times [70, 71]. As 69% of adults report at least one hour of social jetlag, this is a highly prevalent sleep disturbance [71]. However, only a few studies have investigated the metabolic consequences of social jetlag [70, 72-74] and the association with T2DM is still lacking. As the different forms of impaired sleep, such as short sleep duration, napping and insomnia, often cluster, it is also important to assess the conjoint effect of these sleeping problems, both will be done in this thesis.

Main objective

This thesis aims to examine 1) the value of non-modifiable biological factors that could play a role in the development of T2DM and could contribute to the improved characterization of people at risk of developing T2DM and 2) impaired sleep as a possible novel modifiable lifestyle factor associated with T2DM development and progression.

Study populations

The studies described in this thesis, were performed in two prospective general population cohorts; the Hoorn Meal Study and the New Hoorn Study. The Hoorn Meal Study was initiated in the year 2005 and consisted of 208 participants at baseline [75].

After 7 years, a follow-up examination was carried out in which 129 people participated [76]. The New Hoorn Study is a cohort study with the main objective to investigate whether the increasing rates of longevity, physical inactivity and obesity affect the prevalence and risk factors of disturbances in glucose metabolism [77]. The New Hoorn Study was initiated in 2006-2007 and consisted of 2807 participants at baseline [78]. Between 2013-2015, a follow-up visit of the total cohort was conducted in which 1734 people participated [79].

Outline of the thesis

Following this general introduction (chapter 1), the first part of this thesis describes non-modifiable biological factors and their association with T2DM. Chapter 2 describes the prospective association between the incretin responses during an oral glucose tolerance test (OGTT) and mixed meal test (MMT) and fasting glucose levels in the Hoorn Meal Study. In Chapter 3, the prospective association between glucagon responses to an OGTT and MMT and fasting glucose levels in this same study is described. Chapter 4, describes the association between GAD65 antibody levels and incident diabetes in a systematic review and meta-analysis, including new data from the Hoorn Study. In part 2, impaired sleep as a novel modifiable risk factor for T2DM development and progression is described. Chapter 5 describes the cross-sectional association of social jetlag with presence of the metabolic syndrome and T2DM in the New Hoorn Study. In Chapter 6, the cross-sectional association of several sleep-related factors, namely sleep duration, insomnia, napping and sleep medication use with the metabolic syndrome is described. Chapter 7, describes the prevalence of insomnia and insomnia symptoms and its association with metabolic parameters and glycemic control in adults with T2DM in a systematic review and meta-analysis. In the general discussion (chapter 8), the main results are discussed and summarized.

REFERENCES

1. Federation, I.D., IDF Diabetes Atlas. 2017: Brussels, Belgium.
2. American Diabetes, A., Diagnosis and classification of diabetes mellitus. *Diabetes Care*, 2009. 32 Suppl 1: p. S62-7.
3. Faerch, K., A. Hulman, and T.P. Solomon, Heterogeneity of Pre-diabetes and Type 2 Diabetes: Implications for Prediction, Prevention and Treatment Responsiveness. *Curr Diabetes Rev*, 2016. 12(1): p. 30-41.
4. Gerstein, H.C., et al., Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. *Diabetes Res Clin Pract*, 2007. 78(3): p. 305-12.
5. Tabak, A.G., et al., Prediabetes: a high-risk state for diabetes development. *Lancet*, 2012. 379(9833): p. 2279-90.
6. Faerch, K., et al., Trajectories of cardiometabolic risk factors before diagnosis of three subtypes of type 2 diabetes: a post-hoc analysis of the longitudinal Whitehall II cohort study. *Lancet Diabetes Endocrinol*, 2013. 1(1): p. 43-51.
7. Ahlqvist, E., et al., Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol*, 2018. 6(5): p. 361-369.
8. Poulsen, P., et al., Increased risk of type 2 diabetes in elderly twins. *Diabetes*, 2009. 58(6): p. 1350-5.
9. Sanghera, D.K. and P.R. Blackett, Type 2 Diabetes Genetics: Beyond GWAS. *J Diabetes Metab*, 2012. 3(198).
10. Mahajan, A., et al., Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. *Nat Genet*, 2018. 50(11): p. 1505-1513.
11. Meeks, K.A., et al., Disparities in type 2 diabetes prevalence among ethnic minority groups resident in Europe: a systematic review and meta-analysis. *Intern Emerg Med*, 2016. 11(3): p. 327-40.
12. Snijder, M.B., et al., Case Finding and Medical Treatment of Type 2 Diabetes among Different Ethnic Minority Groups: The HELIUS Study. *J Diabetes Res*, 2017. 2017: p. 9896849.
13. Uitewaal, P.J., et al., Prevalence of type 2 diabetes mellitus, other cardiovascular risk factors, and cardiovascular disease in Turkish and Moroccan immigrants in North West Europe: a systematic review. *Prev Med*, 2004. 39(6): p. 1068-76.
14. Chang, A.M. and J.B. Halter, Aging and insulin secretion. *Am J Physiol Endocrinol Metab*, 2003. 284(1): p. E7-12.
15. Koopman, R.J., et al., Changes in age at diagnosis of type 2 diabetes mellitus in the United States, 1988 to 2000. *Ann Fam Med*, 2005. 3(1): p. 60-3.
16. Organization, W.H., Global report on diabetes. 2016.
17. Okamura, T., et al., Ectopic fat obesity presents the greatest risk for incident type 2 diabetes: a population-based longitudinal study. *Int J Obes (Lond)*, 2018.
18. Felber, J.P. and A. Golay, Pathways from obesity to diabetes. *Int J Obes Relat Metab Disord*, 2002. 26 Suppl 2: p. S39-45.
19. Maddatu, J., E. Anderson-Baucum, and C. Evans-Molina, Smoking and the risk of type 2 diabetes. *Transl Res*, 2017. 184: p. 101-107.
20. Organization, W.H., Global Recommendations on Physical Activity for Health. 2010.
21. Sedentary Behaviour Research, N., Letter to the editor: standardized use of the terms "sedentary" and "sedentary behaviours". *Appl Physiol Nutr Metab*, 2012. 37(3): p. 540-2.

22. Smith, A.D., et al., Physical activity and incident type 2 diabetes mellitus: a systematic review and dose-response meta-analysis of prospective cohort studies. *Diabetologia*, 2016. 59(12): p. 2527-2545.
23. Biswas, A., et al., Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and meta-analysis. *Ann Intern Med*, 2015. 162(2): p. 123-32.
24. Hu, F.B., et al., Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. *JAMA*, 2003. 289(14): p. 1785-91.
25. Pan, A., et al., Changes in red meat consumption and subsequent risk of type 2 diabetes mellitus: three cohorts of US men and women. *JAMA Intern Med*, 2013. 173(14): p. 1328-35.
26. van Dam, R.M., et al., Dietary fat and meat intake in relation to risk of type 2 diabetes in men. *Diabetes Care*, 2002. 25(3): p. 417-24.
27. Imamura, F., et al., Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. *Br J Sports Med*, 2016. 50(8): p. 496-504.
28. InterAct, C., et al., Consumption of sweet beverages and type 2 diabetes incidence in European adults: results from EPIC-InterAct. *Diabetologia*, 2013. 56(7): p. 1520-30.
29. Montonen, J., et al., Consumption of sweetened beverages and intakes of fructose and glucose predict type 2 diabetes occurrence. *J Nutr*, 2007. 137(6): p. 1447-54.
30. Muraki, I., et al., Fruit consumption and risk of type 2 diabetes: results from three prospective longitudinal cohort studies. *BMJ*, 2013. 347: p. f5001.
31. Bazzano, L.A., et al., Intake of fruit, vegetables, and fruit juices and risk of diabetes in women. *Diabetes Care*, 2008. 31(7): p. 1311-7.
32. Liu, S., et al., A prospective study of whole-grain intake and risk of type 2 diabetes mellitus in US women. *Am J Public Health*, 2000. 90(9): p. 1409-15.
33. Meyer, K.A., et al., Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. *Am J Clin Nutr*, 2000. 71(4): p. 921-30.
34. Ley, S.H., et al., Prevention and management of type 2 diabetes: dietary components and nutritional strategies. *Lancet*, 2014. 383(9933): p. 1999-2007.
35. van Dam, R.M., et al., Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. *Ann Intern Med*, 2002. 136(3): p. 201-9.
36. McIntyre, N., C.D. Holdsworth, and D.S. Turner, New Interpretation of Oral Glucose Tolerance. *Lancet*, 1964. 2(7349): p. 20-1.
37. Perley, M.J. and D.M. Kipnis, Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. *J Clin Invest*, 1967. 46(12): p. 1954-62.
38. Nauck, M., et al., Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. *Diabetologia*, 1986. 29(1): p. 46-52.
39. Shah, P., et al., Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. *J Clin Endocrinol Metab*, 2000. 85(11): p. 4053-9.
40. Alsema, M., et al., Preserved GLP-1 and exaggerated GIP secretion in type 2 diabetes and relationships with triglycerides and ALT. *Eur J Endocrinol*, 2013. 169(4): p. 421-30.
41. Faerch, K., et al., Insulin Resistance Is Accompanied by Increased Fasting Glucagon and Delayed Glucagon Suppression in Individuals With Normal and Impaired Glucose Regulation. *Diabetes*, 2016. 65(11): p. 3473-3481.
42. Knop, F.K., et al., Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. *Diabetologia*, 2007. 50(4): p. 797-805.

43. Baekkeskov, S., et al., Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. *Nature*, 1990. 347(6289): p. 151-6.
44. Lee, S.A., et al., Progression to insulin deficiency in Korean patients with Type 2 diabetes mellitus positive for anti-GAD antibody. *Diabet Med*, 2011. 28(3): p. 319-24.
45. Niskanen, L.K., et al., GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. *Diabetes Care*, 1995. 18(12): p. 1557-65.
46. Takino, H., et al., Antibodies to GAD in Japanese patients classified as Type 2 diabetes at diagnosis. High titre of GAD Ab is a predictive marker for early insulin treatment--report of west Japan (Kyushu, Yamaguchi, Osaka) study for GAD Ab(+) diabetes. *Diabet Med*, 2002. 19(9): p. 730-4.
47. Turner, R., et al., UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. *Lancet*, 1997. 350(9087): p. 1288-93.
48. Lethagen, A.L., et al., Glutamic acid decarboxylase antibody positivity is associated with an impaired insulin response to glucose and arginine in nondiabetic patients with autoimmune thyroiditis. *J Clin Endocrinol Metab*, 2002. 87(3): p. 1177-83.
49. Bosi, E.P., et al., Low prevalence of islet autoimmunity in adult diabetes and low predictive value of islet autoantibodies in the general adult population of northern Italy. *Diabetologia*, 1999. 42(7): p. 840-4.
50. Dabelea, D., et al., Diabetes autoantibodies do not predict progression to diabetes in adults: the Diabetes Prevention Program. *Diabet Med*, 2014. 31(9): p. 1064-8.
51. Hampe, C.S., et al., Longitudinal changes in epitope recognition of autoantibodies against glutamate decarboxylase 65 (GAD65Ab) in prediabetic adults developing diabetes. *Clin Exp Immunol*, 2007. 148(1): p. 72-8.
52. Lundgren, V.M., et al., GAD antibody positivity predicts type 2 diabetes in an adult population. *Diabetes*, 2010. 59(2): p. 416-22.
53. Sorgjerd, E.P., et al., Presence of anti-GAD in a non-diabetic population of adults; time dynamics and clinical influence: results from the HUNT study. *BMJ Open Diabetes Res Care*, 2015. 3(1): p. e000076.
54. Leger, D., et al., An international survey of sleeping problems in the general population. *Curr Med Res Opin*, 2008. 24(1): p. 307-17.
55. Rowshan Ravan, A., et al., Thirty-six-year secular trends in sleep duration and sleep satisfaction, and associations with mental stress and socioeconomic factors--results of the Population Study of Women in Gothenburg, Sweden. *J Sleep Res*, 2010. 19(3): p. 496-503.
56. Hersenstichting, N., Factsheet Resultaten Slaaponderzoek Hersenstichting. 2017.
57. Roth, T., Insomnia: definition, prevalence, etiology, and consequences. *J Clin Sleep Med*, 2007. 3(5 Suppl): p. S7-10.
58. Knutson, K.L., et al., The metabolic consequences of sleep deprivation. *Sleep Med Rev*, 2007. 11(3): p. 163-78.
59. Schmid, S.M., M. Hallschmid, and B. Schultes, The metabolic burden of sleep loss. *Lancet Diabetes Endocrinol*, 2015. 3(1): p. 52-62.
60. Spiegel, K., et al., Leptin levels are dependent on sleep duration: relationships with sympathovagal balance, carbohydrate regulation, cortisol, and thyrotropin. *J Clin Endocrinol Metab*, 2004. 89(11): p. 5762-71.
61. Spiegel, K., et al., Effects of poor and short sleep on glucose metabolism and obesity risk. *Nat Rev Endocrinol*, 2009. 5(5): p. 253-61.
62. Taheri, S., et al., Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased body mass index. *PLoS Med*, 2004. 1(3): p. e62.

63. Van Cauter, E., et al., Impact of sleep and sleep loss on neuroendocrine and metabolic function. *Horm Res*, 2007. 67 Suppl 1: p. 2-9.
64. Spiegel, K., et al., Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. *Ann Intern Med*, 2004. 141(11): p. 846-50.
65. Zimberg, I.Z., et al., Short sleep duration and obesity: mechanisms and future perspectives. *Cell Biochem Funct*, 2012. 30(6): p. 524-9.
66. Reutrakul, S. and E. Van Cauter, Interactions between sleep, circadian function, and glucose metabolism: implications for risk and severity of diabetes. *Ann N Y Acad Sci*, 2014. 1311: p. 151-73.
67. Cappuccio, F.P., et al., Quantity and quality of sleep and incidence of type 2 diabetes: a systematic review and meta-analysis. *Diabetes Care*, 2010. 33(2): p. 414-20.
68. Katic, B., et al., New approach for analyzing self-reporting of insomnia symptoms reveals a high rate of comorbid insomnia across a wide spectrum of chronic diseases. *Sleep Med*, 2015. 16(11): p. 1332-1341.
69. Bilge, N.S.Y., et al., Comparison of the frequency of sleep disorders among patients with rheumatoid arthritis and type 2 diabetic patients. *Konuralp Tip Dergisi*, 2016. 8(2): p. 100-103.
70. Roenneberg, T., et al., Social jetlag and obesity. *Curr Biol*, 2012. 22(10): p. 939-43.
71. Wittmann, M., et al., Social jetlag: misalignment of biological and social time. *Chronobiol Int*, 2006. 23(1-2): p. 497-509.
72. Kantermann, T., et al., Atherosclerotic risk and social jetlag in rotating shift-workers: first evidence from a pilot study. *Work*, 2013. 46(3): p. 273-82.
73. Parsons, M.J., et al., Social jetlag, obesity and metabolic disorder: investigation in a cohort study. *Int J Obes (Lond)*, 2015. 39(5): p. 842-8.
74. Rutters, F., et al., Is social jetlag associated with an adverse endocrine, behavioral, and cardiovascular risk profile? *J Biol Rhythms*, 2014. 29(5): p. 377-83.
75. Rijkkelijkhuizen, J.M., et al., Classical and model-based estimates of beta-cell function during a mixed meal vs. an OGTT in a population-based cohort. *Diabetes Res Clin Pract*, 2009. 83(2): p. 280-8.
76. Koopman, A.D.M., et al., Incretin responses to oral glucose and mixed meal tests and changes in fasting glucose levels during 7 years of follow-up: The Hoorn Meal Study. *PLoS One*, 2018. 13(1): p. e0191114.
77. Rutters, F., et al., Cohort Profile: The Hoorn Studies. *Int J Epidemiol*, 2018. 47(2): p. 396-396j.
78. van 't Riet, E., et al., Relationship between A1C and glucose levels in the general Dutch population: the new Hoorn study. *Diabetes Care*, 2010. 33(1): p. 61-6.
79. Koopman, A.D.M., et al., The Association between Social Jetlag, the Metabolic Syndrome, and Type 2 Diabetes Mellitus in the General Population: The New Hoorn Study. *J Biol Rhythms*, 2017. 32(4): p. 359-368.

